Clinical Trials Logo

Clinical Trial Summary

Remimazolam is a ultra-short-acting benzodiazepine that is rapidly metabolized in the body by tissue esterase and not accumulates in the body for long periods of infusion. In addition, similar to other benzodiazepines, it is possible to reverse the sedation and anesthetic effects through flumazenil. It has no injection pain and infusion syndrome compared with propofol. There is no study to investigate overall postoperative functional recovery via QoR-15 in patients receiving TIVA using remimazolam. The purpose of this study is to determine whether there is any difference in the quality of postoperative recovery between propofol-based and remimazolam-based total intravenous anesthesia in female patients undergoing thyroidectomy. The QoR-15 questionnaire score, pain, nausea/vomiting, and the frequency of complications are evaluated and compared between the two groups.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05016518
Study type Interventional
Source Gangnam Severance Hospital
Contact
Status Completed
Phase N/A
Start date September 16, 2021
Completion date May 20, 2022